Next Article in Journal
Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer
Previous Article in Journal
Serum C-Reactive Protein Predicts Poor Prognosis in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 1
10.3747/co.21.2043
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Concurrent Chemoradiotherapy for Locally Advanced Breast Cancer—Time for a New Paradigm?

by
V. Mandilaras
1,
N. Bouganim
1,*,
J. Spayne
2,
R. Dent
3,
A. Arnaout
4,
J.F. Boileau
5,
M. Brackstone
6,
S. Meterissian
7 and
M. Clemons
8
1
Department of Medical Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada
2
Division of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3
Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4
Ottawa Hospital Cancer Centre and Ottawa Hospital Research Institute, Ottawa, ON, Canada
5
Department of Oncology, Jewish General Hospital and Segal Cancer Centre, Montreal, QC, Canada
6
London Regional Cancer Program, Division of General Surgery/Surgical Oncology, London, ON, Canada
7
Department of Surgical Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada
8
Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(1), 25-32; https://doi.org/10.3747/co.21.2043
Submission received: 4 November 2014 / Revised: 3 December 2014 / Accepted: 6 January 2015 / Published: 1 February 2015

Abstract

Background: In cases of locally advanced breast cancer (labc), preoperative (“neoadjuvant”) therapy was traditionally reserved to render the patient operable. More recently, neoadjuvant therapy, particularly chemotherapy, is being used in patients with operable disease to increase the opportunity for breast conservation. Despite the increasing use of preoperative chemotherapy, rates of pathologic complete response, a surrogate marker for disease-free survival, remain modest in patients with locally advanced disease and particularly so when the tumour is estrogen or progesterone receptor–positive and her2-negative. A new paradigm for labc patients is needed. In other solid tumours (for example, rectal, esophageal, and lung cancers), concurrent chemoradiotherapy (ccrt) is routinely used in neoadjuvant and adjuvant treatment protocols alike. Results: The literature suggests that ccrt in labc patients with inoperable disease is associated with response rates higher than would be anticipated with systemic therapy alone. Conclusions: Ongoing trials in this field are eagerly awaited to determine if ccrt should become the new paradigm.
Keywords: breast cancer; concurrent chemoradiotherapy; neoadjuvant therapy; locally advanced disease breast cancer; concurrent chemoradiotherapy; neoadjuvant therapy; locally advanced disease

Share and Cite

MDPI and ACS Style

Mandilaras, V.; Bouganim, N.; Spayne, J.; Dent, R.; Arnaout, A.; Boileau, J.F.; Brackstone, M.; Meterissian, S.; Clemons, M. Concurrent Chemoradiotherapy for Locally Advanced Breast Cancer—Time for a New Paradigm? Curr. Oncol. 2015, 22, 25-32. https://doi.org/10.3747/co.21.2043

AMA Style

Mandilaras V, Bouganim N, Spayne J, Dent R, Arnaout A, Boileau JF, Brackstone M, Meterissian S, Clemons M. Concurrent Chemoradiotherapy for Locally Advanced Breast Cancer—Time for a New Paradigm? Current Oncology. 2015; 22(1):25-32. https://doi.org/10.3747/co.21.2043

Chicago/Turabian Style

Mandilaras, V., N. Bouganim, J. Spayne, R. Dent, A. Arnaout, J.F. Boileau, M. Brackstone, S. Meterissian, and M. Clemons. 2015. "Concurrent Chemoradiotherapy for Locally Advanced Breast Cancer—Time for a New Paradigm?" Current Oncology 22, no. 1: 25-32. https://doi.org/10.3747/co.21.2043

APA Style

Mandilaras, V., Bouganim, N., Spayne, J., Dent, R., Arnaout, A., Boileau, J. F., Brackstone, M., Meterissian, S., & Clemons, M. (2015). Concurrent Chemoradiotherapy for Locally Advanced Breast Cancer—Time for a New Paradigm? Current Oncology, 22(1), 25-32. https://doi.org/10.3747/co.21.2043

Article Metrics

Back to TopTop